Effects of Tibolone on cardiovascular disease in menopausal wome
Not Applicable
- Conditions
- cardiovascular markers.Drugs,medicaments and biological substances causing adverse effects in therapeutic use
- Registration Number
- IRCT138901293743N1
- Lead Sponsor
- Tarbiat Modares University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 150
Inclusion Criteria
healthy non-surgical postmenopausal women (more than one year since the last menstrual period and plasma 17-ß-estradiol level <35 pg/ml), age 45-60 years .
Exclusion criteria: receiving cholesterol-lowering agent, estrogen therapy, antioxidant vitamin supplements during the preceding six months, any contra-indications to HRT, dyslipidemia (cholesterol (CHOL)> 250 mg/dl and/or triglyceride (TG) > 150 mg/dl), smoking, presence of diabetes, previous angina, or hypertension
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum lipid. Timepoint: Baseline and after six months. Method of measurement: enzymatic method.
- Secondary Outcome Measures
Name Time Method CRP. Timepoint: Baseline and after six months. Method of measurement: immuno turb.;BMI. Timepoint: at first and after six months. Method of measurement: meter weight.;SHBG. Timepoint: Baseline and after six months. Method of measurement: ELISA.;FTI. Timepoint: Baseline and after six months. Method of measurement: ELISA.;FEI. Timepoint: Baseline and after six months. Method of measurement: ELISA.